ACTHAR GEL (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
When do Acthar Gel (autoinjector) patents expire, and what generic alternatives are available?
Acthar Gel (autoinjector) is a drug marketed by Mallinckrodt Ard and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in ACTHAR GEL (AUTOINJECTOR) is corticotropin. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the corticotropin profile page.
DrugPatentWatch® Generic Entry Outlook for Acthar Gel (autoinjector)
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACTHAR GEL (AUTOINJECTOR)?
- What are the global sales for ACTHAR GEL (AUTOINJECTOR)?
- What is Average Wholesale Price for ACTHAR GEL (AUTOINJECTOR)?
Summary for ACTHAR GEL (AUTOINJECTOR)
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ACTHAR GEL (AUTOINJECTOR) at DailyMed |
-patent-expirations.png "ACTHAR GEL (AUTOINJECTOR) drug patent expirations")
Pharmacology for ACTHAR GEL (AUTOINJECTOR)
| Drug Class | Adrenocorticotropic Hormone |
US Patents and Regulatory Information for ACTHAR GEL (AUTOINJECTOR)
ACTHAR GEL (AUTOINJECTOR) is protected by three US patents.
Patents protecting ACTHAR GEL (AUTOINJECTOR)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ard | ACTHAR GEL (AUTOINJECTOR) | corticotropin | INJECTABLE;INJECTION | 008372-003 | Feb 29, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mallinckrodt Ard | ACTHAR GEL (AUTOINJECTOR) | corticotropin | INJECTABLE;INJECTION | 008372-004 | Feb 29, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
